Adjuvant interferon-α for the treatment of high-risk melanoma: An individual patient data meta-analysis
Natalie Ives(Cancer Research UK Clinical Trials Unit), John M. Kirkwood(UPMC Hillman Cancer Center), David Cameron(Corewell Health), Keith Wheatley(Cancer Research UK Clinical Trials Unit), Rebecca A. Harrison(BC Cancer Agency), Rosaria Bufalino, Alexander M.M. Eggermont(University Medical Center Utrecht), Paul Lorigan(Manchester Academic Health Science Centre), Stefan Suciu(St James's University Hospital), Vera J. Suman(Mayo Clinic in Arizona), Svetomir N. Markovic(Mayo Clinic in Arizona), Michael Kressig, Jerry Marsden, Lesley Turner, Natale Cascinelli, Valerie Doherty, Barry W. Hancock(Weston Park Cancer Centre), Rona M. MacKie(University of Glasgow), Claus Garbe(University of Tübingen), Martin Gore(Imperial College London)
Cited by 170
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Final Version of 2009 AJCC Melanoma Staging and Classification
|Journal of Clinical Oncology|2009|4.6k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
Melanoma staging: Evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual
|CA A Cancer Journal for Clinicians|2017|2.3k